• Revenue from continuing operations increased 27% to $1.66 million
• Other income from R&D grant increased 14% to $1.37 million
• Net loss attributable to members decreased 4% to $3.16 million

PainChek Ltd, a leading digital health company, has reported its financial results for the half-year ended 31 December 2024. The company's revenue from continuing operations increased 27% to $1.66 million, while other income from R&D grants grew 14% to $1.37 million, resulting in a 21% increase in total revenue and other income to $3.03 million. The net loss attributable to members decreased 4% to $3.16 million during the period. The company's key strategic priorities include expanding into the US market, continuing growth in the adult app, and the direct-to-parent market entry of the infant app. PainChek has also maintained its ISO/IEC 27001 certification for information security management and is investing in research and development to expand its capabilities. The company recently completed an underwritten Entitlement Offer to raise $5.12 million, which will support its growth initiatives.

PainChek has contracted approximately 100,000 licences across almost 1,800 aged care facilities, with an annual recurring revenue (ARR) of $4.8 million once the licences are fully implemented. This represents a 23% increase in contracted ARR over the prior corresponding period.

PainChek is anticipating FDA regulatory clearance for its adult app in the first half of 2025, which will enable the company to expand into the large US healthcare market. The company is also focused on building its presence in the home care and hospital markets, as well as the direct-to-consumer market for its infant app.